{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T08:42:46Z","timestamp":1792572166816,"version":"4.5.0"},"reference-count":22,"publisher":"American Chemical Society (ACS)","issue":"10","license":[{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-001"},{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-009"},{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"}],"funder":[{"DOI":"10.13039\/100000928","name":"Welch Foundation","doi-asserted-by":"publisher","award":["C-1970"],"award-info":[{"award-number":["C-1970"]}],"id":[{"id":"10.13039\/100000928","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012394","name":"Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012394","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["HT9425-23-1-0494"],"award-info":[{"award-number":["HT9425-23-1-0494"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["HT9425-25-1-0021"],"award-info":[{"award-number":["HT9425-25-1-0021"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-21-1-0789"],"award-info":[{"award-number":["W81XWH-21-1-0789"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Institutes of Health (NIH)","award":["R01-AI165079"],"award-info":[{"award-number":["R01-AI165079"]}]},{"name":"National Institutes of Health (NIH)","award":["R01-CA277838"],"award-info":[{"award-number":["R01-CA277838"]}]},{"name":"National Institutes of Health (NIH)","award":["R35-GM133706"],"award-info":[{"award-number":["R35-GM133706"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Therapeutic antibodies have transformed the treatment of cancer, inflammation, infection, and disorders of bone biology by recognizing disease-associated molecular targets with high specificity. However, achieving therapeutically effective antibody concentrations at the site of disease remains a major challenge, as systemic administration does not inherently result in efficient tissue-specific delivery. Bone is a particularly demanding destination because mineralized matrix, limited vascular access, marrow complexity, and active remodeling can restrict local antibody exposure. Recent advances in bone-targeting antibody design point to a powerful reframing in which antibodies can be engineered not only for antigen specificity but also for tissue specificity. By attaching hydroxyapatite-binding motifs such as bisphosphonates or acidic peptides, antibodies can be endowed with bone-homing capabilities. The efficacy of this strategy has now been validated across multiple preclinical disease models, including breast cancer bone metastasis and osteoporosis-related bone loss. The next challenge is to define how affinity, valency, conjugation site, circulation time, and release should be tuned for each skeletal disease.<\/jats:p>","DOI":"10.1021\/acs.bioconjchem.6c00415","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T16:02:38Z","timestamp":1790179358000},"page":"1943-1948","source":"Crossref","is-referenced-by-count":0,"title":["Bone-Targeting Antibodies for Skeletal Precision Therapy"],"prefix":"10.1021","volume":"37","author":[{"given":"Boyang","family":"Zhou","sequence":"first","affiliation":[{"name":"Rice University , , 6100 Main Street , , ,","place":["Houston, Texas, United States, 77005"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4311-971X","authenticated-orcid":true,"given":"Han","family":"Xiao","sequence":"additional","affiliation":[{"name":"Rice University , , 6100 Main Street , , ,","place":["Houston, Texas, United States, 77005"]},{"name":"Rice University , , 6100 Main Street , , ,","place":["Houston, Texas, United States, 77005"]},{"name":"Rice University , , 6100 Main Street , , ,","place":["Houston, Texas, United States, 77005"]},{"name":"Rice University , , 6100 Main Street , , ,","place":["Houston, Texas, United States, 77005"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"issue":"4","key":"2026102103083539200_cit1","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/nrc3236","article-title":"Antibody therapy of cancer","volume":"12","author":"Scott","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"2026102103083539200_cit2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1146\/annurev-med-050311-201823","article-title":"Antibody-drug conjugates in cancer therapy","volume":"64","author":"Sievers","year":"2013","journal-title":"Annu. Rev. Med."},{"issue":"1","key":"2026102103083539200_cit3","doi-asserted-by":"publisher","first-page":"20","DOI":"10.7497\/j.issn.2095-3941.2014.01.002","article-title":"Mechanistic considerations for the use of monoclonal antibodies for cancer therapy","volume":"11","author":"Glassman","year":"2014","journal-title":"Cancer Biol. Med."},{"issue":"1","key":"2026102103083539200_cit4","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s10928-011-9232-2","article-title":"Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human","volume":"39","author":"Shah","year":"2012","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"issue":"6","key":"2026102103083539200_cit5","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/nrc3055","article-title":"Cancer to bone: a fatal attraction","volume":"11","author":"Weilbaecher","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"2026102103083539200_cit6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2015\/421746","article-title":"Biology of Bone Tissue: Structure, Function, and Factors That Influence Bone Cells","volume":"2015","author":"Florencio-Silva","year":"2015","journal-title":"BioMed Res. Int."},{"issue":"3","key":"2026102103083539200_cit7","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.cell.2007.05.047","article-title":"Endocrine regulation of energy metabolism by the skeleton","volume":"130","author":"Lee","year":"2007","journal-title":"Cell"},{"issue":"16","key":"2026102103083539200_cit8","doi-asserted-by":"publisher","first-page":"4295","DOI":"10.7150\/thno.26370","article-title":"Comparative biodistribution analysis across four different (89)Zr-monoclonal antibody tracers-The first step towards an imaging warehouse","volume":"8","author":"Bensch","year":"2018","journal-title":"Theranostics"},{"issue":"3","key":"2026102103083539200_cit9","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"2026102103083539200_cit10","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.prro.2022.03.004","article-title":"Radium-223 for Metastatic Castrate-Resistant Prostate Cancer","volume":"12","author":"Sindhu","year":"2022","journal-title":"Pract Radiat Oncol"},{"issue":"26","key":"2026102103083539200_cit11","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abf2051","article-title":"Harnessing the power of antibodies to fight bone metastasis","volume":"7","author":"Tian","year":"2021","journal-title":"Sci. Adv."},{"issue":"5","key":"2026102103083539200_cit12","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1016\/j.ymthe.2024.03.001","article-title":"Engineering small-molecule and protein drugs for targeting bone tumors","volume":"32","author":"Wang","year":"2024","journal-title":"Mol. Ther."},{"key":"2026102103083539200_cit13","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.bonr.2018.06.007","article-title":"Bisphosphonate conjugation for bone specific drug targeting","volume":"9","author":"Farrell","year":"2018","journal-title":"Bone Rep."},{"issue":"5","key":"2026102103083539200_cit14","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1021\/mp050017u","article-title":"Imparting mineral affinity to fetuin by bisphosphonate conjugation: a comparison of three bisphosphonate conjugation schemes","volume":"2","author":"Gittens","year":"2005","journal-title":"Mol Pharm"},{"issue":"3","key":"2026102103083539200_cit15","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1021\/acscentsci.1c01024","article-title":"Bone-Specific Enhancement of Antibody Therapy for Breast Cancer Metastasis to Bone","volume":"8","author":"Tian","year":"2022","journal-title":"ACS Cent. Sci."},{"issue":"12","key":"2026102103083539200_cit16","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1016\/j.addr.2008.04.012","article-title":"Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance","volume":"60","author":"Thurber","year":"2008","journal-title":"Adv Drug Deliv Rev"},{"issue":"6","key":"2026102103083539200_cit17","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/s8756-3282(00)00392-6","article-title":"Functional analysis of bone sialoprotein: identification of the hydroxyapatite-nucleating and cell-binding domains by recombinant peptide expression and site-directed mutagenesis","volume":"27","author":"Harris","year":"2000","journal-title":"Bone"},{"issue":"4","key":"2026102103083539200_cit18","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1007\/s00223-013-9698-6","article-title":"Role of osteopontin in modulation of hydroxyapatite formation","volume":"93","author":"Hunter","year":"2013","journal-title":"Calcif. Tissue Int."},{"issue":"20","key":"2026102103083539200_cit19","doi-asserted-by":"publisher","first-page":"6243s","DOI":"10.1158\/1078-0432.Ccr-06-0931","article-title":"Clinical features of metastatic bone disease and risk of skeletal morbidity","volume":"12","author":"Coleman","year":"2006","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"2026102103083539200_cit20","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1038\/nrc867","article-title":"Metastasis to bone: causes, consequences and therapeutic opportunities","volume":"2","author":"Mundy","year":"2002","journal-title":"Nat. Rev. Cancer"},{"issue":"6","key":"2026102103083539200_cit21","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1093\/jbmr\/zjae050","article-title":"Affinity targeting of therapeutic proteins to the bone surface-local delivery of sclerostin-neutralizing antibody enhances efficacy","volume":"39","author":"Zhang","year":"2024","journal-title":"J. Bone Miner. Res."},{"issue":"4","key":"2026102103083539200_cit22","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1158\/2159-8290.Cd-23-0543","article-title":"Bone-Induced HER2 Promotes Secondary Metastasis in HR+\/HER2- Breast Cancer","volume":"15","author":"Alam","year":"2025","journal-title":"Cancer Discov"}],"container-title":["Bioconjugate Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.bioconjchem.6c00415","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/bcches\/article-pdf\/37\/10\/1943\/68623428\/bc6c00415.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/bcches\/article-pdf\/37\/10\/1943\/68623428\/bc6c00415.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T08:11:35Z","timestamp":1792570295000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/bcches\/article\/37\/10\/1943\/5436762\/Bone-Targeting-Antibodies-for-Skeletal-Precision"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,23]]},"references-count":22,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,9,23]]},"published-print":{"date-parts":[[2026,10,21]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.bioconjchem.6c00415","relation":{},"ISSN":["1043-1802","1520-4812"],"issn-type":[{"value":"1043-1802","type":"print"},{"value":"1520-4812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,23]]}}}